We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Optical System Illuminates Cardiac Ablation Procedures

By HospiMedica International staff writers
Posted on 04 Jan 2016
An optical tissue characterization system for use during cardiac ablation allows cardiologists to continuously “see” into heart tissue.

The LuxCath system is intended for the treatment of all arrhythmias that require a cardiac ablation procedure, including atrial fibrillation (AF), atrial flutter, AV nodal reentrant tachycardia (AVNRT), and others. More...
The optical technology is used to directly interrogate cardiac tissue with light prior to and during ablation in order to identify tissue contact, visualize lesions, and detect lesion gaps in real-time, all without using pressure sensors or ultrasound.

The system delivers illumination and retrieves tissue fluorescence via an optical fiber with the intention of providing better tissue contact and lesion formation assessment during ablation to reduce procedure times, fluoroscopy times, arrhythmia recurrences, and costs. The LuxCath system is a product of LuxCath (Boston, MA, USA) and can be utilized as a standalone catheter or as an embedded optical technology that can be integrated into an existing ablation catheter.

“The technology identified tissue contact and was easy to use in a wide variety of settings, and we were able to assess and monitor ablation lesions as they were being created. There were no complications,” said Vivek Reddy, MD, who led the first-in-man clinical trial in 11 arrhythmia patients at Homolka Hospital (Prague, Czech Republic) conducted during December 2015. “This is an exciting step forward in the world of ablation. Based on our experience, the technology platform is quite promising.”

“We are thrilled with the performance of our optical tissue interrogation system for contact and lesion progression assessment,” said Omar Amirana, MD, CEO of LuxCath and senior vice president of its parent company, Allied Minds (Boston, MA, USA). “Given the potential to positively impact all ablation procedures, we are excited to advance the technology into the marketplace. This is an enormous milestone for the company.”

AF occurs when the heart's two upper chambers beat erratically. In one form of the condition, paroxysmal AF, patients have bouts of erratic beats that begin spontaneously and usually last less than a week. AF and other arrhythmias can lead to serious adverse events such as thrombi travelling from the heart to obstruct arteries supplying the brain, causing stroke, or thrombi in other parts of the body, causing tissue damage.

Related Links:

LuxCath
Allied Minds



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.